Literature DB >> 19151961

[Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases].

M Alter1, M Wittmann, B Völker, A Kapp, T Werfel, R Gutzmer.   

Abstract

Treatment of autoimmune bullous diseases, especially of the pemphigus diseases, regularly requires the use of immunosuppressive drugs, often with insufficient clinical benefit but considerable side effects. A variety of autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, pemphigus vulgaris) have been successfully treated with rituximab, a chimeric monoclonal antibody against CD20, leading to a transient depletion of B cells. We report on three patients with pemphigus foliaceus who responded to rituximab after failing multiple other immunosuppressive therapies. We also examine the controversial issue of continuation therapy with rituximab in detail.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151961     DOI: 10.1007/s00105-008-1682-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  14 in total

1.  Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab.

Authors:  M Goebeler; S Herzog; E-B Bröcker; D Zillikens
Journal:  Br J Dermatol       Date:  2003-10       Impact factor: 9.302

2.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Authors:  A Razzaque Ahmed; Zachary Spigelman; Lisa A Cavacini; Marshall R Posner
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

Review 3.  Rituximab: applications in dermatology.

Authors:  Mitra M Fatourechi; Rokea A el-Azhary; Lawrence E Gibson
Journal:  Int J Dermatol       Date:  2006-10       Impact factor: 2.736

4.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.

Authors:  M J Arin; A Engert; T Krieg; N Hunzelmann
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

6.  Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.

Authors:  Michael Hertl; Detlef Zillikens; Luca Borradori; Leena Bruckner-Tuderman; Harald Burckhard; Rüdiger Eming; Andreas Engert; Matthias Goebeler; Silke Hofmann; Nicolas Hunzelmann; Franz Karlhofer; Ocko Kautz; Undine Lippert; Andrea Niedermeier; Martin Nitschke; Martin Pfütze; Marcel Reiser; Christian Rose; Enno Schmidt; Iakov Shimanovich; Michael Sticherling; Sonja Wolff-Franke
Journal:  J Dtsch Dermatol Ges       Date:  2008-01-14       Impact factor: 5.584

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

8.  Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Authors:  Angelo V Marzano; Daniele Fanoni; Luigia Venegoni; Emilio Berti; Ruggero Caputo
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 9.  Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.

Authors:  Giuseppe Cianchini; Rosamaria Corona; Alessandra Frezzolini; Marina Ruffelli; Biagio Didona; Pietro Puddu
Journal:  Arch Dermatol       Date:  2007-08

10.  A single cycle of rituximab for the treatment of severe pemphigus.

Authors:  Pascal Joly; Hugo Mouquet; Jean-Claude Roujeau; Michel D'Incan; Danièle Gilbert; Serge Jacquot; Marie-Lise Gougeon; Christophe Bedane; Ralf Muller; Brigitte Dreno; Marie-Sylvie Doutre; Emmanuel Delaporte; Christine Pauwels; Nathalie Franck; Frédéric Caux; Catherine Picard; Emmanuelle Tancrede-Bohin; Philippe Bernard; François Tron; Michael Hertl; Philippe Musette
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

View more
  1 in total

1.  Refractory pemphigus foliaceous treated with rituximab.

Authors:  Fatima Awdeh; Eimear Gilhooley; Ciara O Grady; Maureen Connolly
Journal:  BMJ Case Rep       Date:  2019-05-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.